Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

• ClinicalTrials.gov Identifier: NCT04735536
• Recruitment Status: Completed
• First Posted: February 3, 2021
• Last Update Posted: August 18, 2023
• Sponsor: Cognition Therapeutics
• Collaborator: National Institute on Aging (NIA)
• Information provided by (Responsible Party): Cognition Therapeutics

Study Description

Brief Summary:

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Condition or disease	Intervention/treatment	Phase
Alzheimer Disease	Drug: CT1812; Other: Placebo	Phase 2

Detailed Description:

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

16 participants (8 randomized to 300 mg CT1812, 8 randomly assigned to placebo during each treatment period): the 8 participants randomly assigned to CT1812 in Treatment Period 1 will receive placebo in Treatment Period 2; the 8 participants randomly assigned to placebo in Treatment Period 1 will receive CT1812 in Treatment Period 2.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 16 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease
• Actual Study Start Date: July 9, 2020
• Actual Primary Completion Date: April 26, 2023
• Actual Study Completion Date: April 26, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active Treatment- CT1812; Active Treatment- CT1812 at a dose of 300mg	Drug: CT1812; Active Treatment- CT1812 at a dose of 300mg; Other: Placebo; Placebo Comparator
Placebo Comparator: Control - Placebo; Drug: Placebo Non-active study drug	Drug: CT1812; Active Treatment- CT1812 at a dose of 300mg; Other: Placebo; Placebo Comparator

Outcome Measures

Primary Outcome Measures :

1. Incidence and Severity of Adverse Events [ Time Frame: Baseline through Day 84 ]
   Adverse events will be collected starting at Day 1 through Day 29, through the washout period, and the second 29-day period to evaluate safety. AEs will be assessed by the Investigator for severity and will be coded for summarization using Medical Dictionary for Regulatory Activities (MedDRA® Version 10.1 or higher).
2. EEG Spectral Measures, specifically Relative Theta (4-8 Hz) Power. [ Time Frame: Baseline through Day 84 ]
   The effect of CT1812 on restoring synaptic will be measured through quantitative electroencephalography (EEG), as reflected by relative theta power. The global relative theta power will be analyzed using the analysis of variance (ANOVA) model for a 2-period, 2-treatment crossover study.
3. Plasma concentration of CT1812 [ Time Frame: Baseline through Day 84 ]
   Measurements of pre-dose and pos-dose plasma concentrations of CT1812.

Eligibility Criteria

• Ages Eligible for Study: 50 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Women of non-childbearing potential and men, aged 50 to 85 years, inclusive, with a diagnosis of mild to moderate Alzheimer's disease according to the 2018 NIA-AA criteria and at least a 6-month history of decline in cognitive function documented in the medical record.

   i) Non-childbearing potential for women is defined as postmenopausal (last menses greater than 24 months) or undergone a documented bilateral tubal ligation or hysterectomy. If last menses less than 24 months, a serum follicle stimulating hormone (FSH) value confirming post-menopausal status may be used.

   ii) Male participants who are sexually active with a woman of child-bearing potential must agree to use condoms during the study and for 3 months after last dose. Female partners should also consider using an acceptable means of birth control, though it is not mandatory. Acceptable forms of birth control include abstinence, birth control pills, or any double combination of: intrauterine device (IUD), male or female condom, diaphragm, sponge, and cervical cap.

2. CSF positive for amyloid beta (as defined in the study manual). Historical CSF results will be considered provided the results are consistent with the CSF amyloid beta threshold required for inclusion and following discussion with the medical monitor; however, an LP is still required as part of screening procedures
3. Neuroimaging (MRI) consistent with the clinical diagnosis of Alzheimer's disease and without findings of significant exclusionary abnormalities (see Section 9.3 exclusion criteria no. 4). An historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.
4. MMSE 18-26 inclusive.
5. Geriatric Depression Scale (GDS) ≤ 6 with no active depression (see Section 9.3 exclusion criteria no. 6).
6. Formal education of 8 or more years.
7. Participants must have a caregiver/study partner who in the opinion of the site's Principal Investigator, has contact with the study participant for a sufficient number of hours per week to provide informative responses on the protocol assessments, oversee the administration of study drug, and is willing and able to participate in all study site visits and some study assessments. The caregiver/ study partner must provide written informed consent to participate in the study.
8. Participants living at home or in the community (assisted living acceptable).
9. Participants must have no known history of difficulty swallowing capsules.
10. Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
11. Must consent to apolipoprotein E (APOE) genotyping.
12. Participants shall be generally healthy with mobility (ambulatory or ambulatory-aided, ie, walker or cane), vision and hearing (hearing aid permissible) sufficient for compliance with testing procedures.
13. Must be able to complete all screening evaluations.

Exclusion Criteria:

1. Hospitalization (except for planned procedures) or change of chronic concomitant medication within 1 month prior to screening.
2. Participants living in a continuous care nursing facility.
3. Contraindications to the MRI examination for any reason.
4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (eg, abscess or brain tumor such as meningioma).

5. Clinical or laboratory findings consistent with:

   1. Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down syndrome, etc).
   2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc).
   3. Seizure disorder.
   4. Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values etc).
6. A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. Participants with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry.

7. Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:

   1. Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, alkaline phosphatase > 1.5 ULN, lactate dehydrogenase (LDH) > 1.5 x ULN).
   2. Respiratory insufficiency.
   3. Renal insufficiency eGFR < 50 mL/min based on the CKD-EPI formula,
   4. Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening).
   5. Bradycardia (< 50/min.) or tachycardia (> 100/min.).
   6. Poorly managed hypertension (systolic > 160 mm Hg and/or diastolic > 95 mm Hg) or hypotension (systolic < 90 mm Hg and/or diastolic < 60 mm Hg).
   7. Uncontrolled diabetes in known diabetics, as defined by hemoglobin A1c (HbA1c) > 7.5.
8. History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
9. Seropositive for human immunodeficiency virus (HIV).
10. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for hepatitis B surface antigen [HbsAg] or anti-hepatitis C [HCV] antibody).

11. Clinically significant abnormalities in screening laboratory tests, including:

    a) Hematocrit less than 35% for males and less than 32% for females, absolute neutrophil cell count of <1500/uL (with the exception of a documented history of a chronic benign neutropenia), or platelet cell count of < 120,000/uL; international normalized ratio (INR) > 1.4 or other coagulopathy, confirmed by repeat assessment.

12. Disability that may prevent the participant from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc).

13. Within 4 weeks of screening visit or during the study, concurrent treatment with antipsychotic agents, antiepileptics, centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc), sedatives, opioids, mood stabilizers (e.g., valproate, lithium); or benzodiazepines, with the following exception:

    a) Low dose lorazepam may be used for sedation prior to MRI scan for those participants requiring sedation. At the discretion of the Investigator, 0.5 to 1 mg may be given orally prior to scan with a single repeat dose given if the first dose is ineffective. No more than a total of 2 mg lorazepam may be used for the MRI scan.

14. Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (eg, small bowel disease, Crohn's disease, celiac disease, or liver disease).
15. Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine).
16. Suspected or known drug or alcohol abuse, ie, more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day.
17. Suspected or known allergy to any components of the study treatments.
18. Enrollment in another investigational study or intake of investigational drug within the previous 30 days or 5 half-lives of the investigational drug, whichever is longer.
19. Intake of drugs or substances potentially involved in clinically significant induction or inhibition of CYP3A4 or P-gp mediated drug interactions with CT1812, within 4 weeks or 5 half-lives of the interacting drug prior to administration of CT1812 and throughout the study. Grapefruit juice should be avoided in the 2 weeks prior to dosing and throughout the study. See Appendix A for a complete list of prohibited substances.
20. Exposure to immunomodulators, anti Aβ vaccines, passive immunotherapies for AD (e.g., monoclonal antibodies) within the past 180 days and/or exposure to BACE inhibitors within the past 30 days
21. Anticipated use of nonsteroidal anti-inflammatory drugs (NSAIDs) on more than 14 days from Baseline/Day 1 to Day 182. Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) > 1.4 or other coagulopathy; platelet count of < 120,000/μL; infection at the desired LP site; taking anti-coagulant medication within 90 days of screening (low-dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.
22. Any condition, which in the opinion of the Investigator or the Sponsor, makes the participant unsuitable for inclusion.

Contacts and Locations

Locations

Netherlands

Brain Research Center

Amsterdam, Netherlands

Sponsors and Collaborators

Cognition Therapeutics

National Institute on Aging (NIA)

Investigators

• Principal Investigator: Everard Vijverberg, MD; Brain Research Center, Amsterdam

More Information

• Responsible Party: Cognition Therapeutics
• ClinicalTrials.gov Identifier: NCT04735536
• Other Study ID Numbers: COG0202; RF1AG058710 ( U.S. NIH Grant/Contract ); 2019-003552-36 ( EudraCT Number )
• First Posted: February 3, 2021
• Last Update Posted: August 18, 2023
• Last Verified: August 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders